Beneficial non-targeted effects of BCG--ethical implications for the coming introduction of new TB vaccines.
about
Heterologous immunity between virusesCommentary: Challenging public health orthodoxies--prophesy or heresy?Child survival and BCG vaccination: a community based prospective cohort study in Uganda.One Episode of Self-Resolving Plasmodium yoelii Infection Transiently Exacerbates Chronic Mycobacterium tuberculosis Infection.CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses.Tuberculin status, socioeconomic differences and differences in all-cause mortality: experience from Norwegian cohorts born 1910-49.Tuberculosis: vaccines in the pipeline.Early versus late BCG vaccination in HIV-1-exposed infants in Uganda: study protocol for a randomized controlled trial.The impact of transcriptomics on the fight against tuberculosis: focus on biomarkers, BCG vaccination, and immunotherapy.Tuberculosis vaccines in clinical trials.Do new TB vaccines have a place in the Expanded Program on Immunization?Overview of vaccination trials for control of tuberculosis in cattle, wildlife and humans.Human biomarkers: can they help us to develop a new tuberculosis vaccine?Anti-Infectious Human Vaccination in Historical Perspective.Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.Protective efficacy of different strategies employingMycobacterium lepraeheat-shock protein 65 against tuberculosis
P2860
Q34051846-9C1D232C-E3EE-419C-B0C9-F93A2C88F2A4Q34931364-ADE8223D-3066-4A99-8466-8272C4BF1178Q35127760-4AE7C8C1-C998-4BDA-9AD3-DFC3E6DA1BDAQ36580383-5AAE4817-C6DA-4E1B-B41B-78969104F7FBQ37145296-F2AADEA9-D495-4C1F-8D89-608F3F3C65F7Q37146252-00BC45E4-252D-4C1D-9557-4E68E30DEF4BQ37194790-C4DD0889-BC23-4CA9-928D-82C251F3A8B3Q37731612-A54BB332-F077-40AF-9A2E-419A0D975C88Q37825430-1927D0E3-BC9E-459E-85DB-C5A7A71B9C79Q37878483-909AC022-ABED-45AF-978F-B00E1E1B381BQ37956378-A17398F0-DEB1-4FF8-B980-F24B8918A357Q38156497-353BEECC-7D88-429A-A39E-0A91E9CCDF51Q38839838-BEFB0C9B-655C-4D83-A0D7-1DDB4517C5AAQ40129444-0F199138-494E-452E-8182-3B756955910CQ41884107-1C6DB96E-03A0-47AF-B850-6E69C1D75026Q58863716-1784C8E5-85FA-4578-BD78-2E0407D1F8CD
P2860
Beneficial non-targeted effects of BCG--ethical implications for the coming introduction of new TB vaccines.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Beneficial non-targeted effect ...... troduction of new TB vaccines.
@ast
Beneficial non-targeted effect ...... troduction of new TB vaccines.
@en
Beneficial non-targeted effect ...... troduction of new TB vaccines.
@nl
type
label
Beneficial non-targeted effect ...... troduction of new TB vaccines.
@ast
Beneficial non-targeted effect ...... troduction of new TB vaccines.
@en
Beneficial non-targeted effect ...... troduction of new TB vaccines.
@nl
prefLabel
Beneficial non-targeted effect ...... troduction of new TB vaccines.
@ast
Beneficial non-targeted effect ...... troduction of new TB vaccines.
@en
Beneficial non-targeted effect ...... troduction of new TB vaccines.
@nl
P2093
P1433
P1476
Beneficial non-targeted effect ...... troduction of new TB vaccines.
@en
P2093
P304
P356
10.1016/J.TUBE.2006.02.001
P50
P577
2006-08-08T00:00:00Z